Policy & Regulation
EpimAb Biotherapeutics is Granted US Patent on Core Bispecific Antibody Technology
25 April 2019 - - The United States Patent and Trademark Office (USPTO) has granted the US Patent No. 10,266,608 entitled "Fabs-In-Tandem Immunoglobulin and Uses Thereof," China-based emerging biopharmaceutical company EpimAb Biotherapeutics said.

Based on EpimAb's globally filed first application, this patent broadly covers bispecific antibodies obtained utilizing the company's FIT-Ig technology in a composition of matter claim.

EpimAb is developing multiple programmes based on its FIT-Ig platform for the treatment of various cancers.

Its most advanced product candidate EMB-01, a cMet/EGFR bispecific with a novel mechanism of action was discovered and rapidly developed to the clinic by EpimAb.

It is currently being investigated in a clinical Phase I/II trial in the USA and China.

A second FIT-Ig molecule is currently under preclinical development with further molecules following soon, rapidly growing EpimAb's pipeline of bispecific antibodies.

EpimAb Biotherapeutics is a privately-owned biopharmaceutical R and D company based in Shanghai and Suzhou with a proprietary unique and efficient technology called FIT-Ig (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties, without any mutations, peptide linkers, or non-Ig sequences.

With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients.

EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide.


Related Headlines